“Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients ”, J. Anal. Oncol., vol. 8, pp. 71–76, Nov. 2019, doi: 10.30683/1927-7229.2019.08.10.